id	document	topic	topic_prob	topic_word	plot_x	plot_y	td_x	td_y	td_z
0	0	Hazard Ratio  (and 95% Confidence Intervals)  in Univariate and Multivariate Analysis of Predictors of Major Cardiac Events  (Cardiac Death or Worsening of Heart Failure Leading to Heart Transplantation)	0	15	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.5887737	15.092761	-138.15144	-85.8636	16.104588
1	1	Left Ventricular and Right Ventricular Ejection Fractions, Left Ventricular and Right Ventricular Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations for Both Ventricles in 30 Cases of Left Sided WPW legend	0	25	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-26.751963	-1.2962534	8.86967	-18.365692	-172.31638
2	2	Partial Regression Coefficients  (All Subjects, n = 262)  for Forward Stepwise Linear Regression for Dependent Variables Augmentation Pressure and Augmentation Index    legend	0	14	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-7.7378716	5.3128357	-122.24162	1.3722941	106.4606
3	3	Left Ventricular  (LVEF)  and Right Ventricular  (RVEF)  Ejection Fractions, Left Ventricular  (LVMP)  and Right Ventricular  (RVMP)  Mean Phases, Left-to-Right Mean Phase Difference  (L-RMP)  and Phase Standard Deviations  (LVPSD and RVPSD)  for Both Ventricles in 14 Cases of Right Sided WPW legend	0	30	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-26.751284	-1.296099	175.9955	-13.258205	11.564963
4	4	Predictors of Mortality by Multivariable Analysis: Variables Are Shown in the Order They Entered a Stepwise Cox Regression Model	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.5161123	9.251663	-71.71737	-23.657705	41.6776
5	5	Logistic Regression Models for Pre- and Post-Transplant Predictors for Normalization of Left Ventricular Ejection Fraction  (LVEF 50%)  in the Post-Transplant Period  (Reference Group: Group With LVEF 50% in the Post-Transplant Period)	0	19	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-0.8104641	16.026785	-103.85996	42.83773	148.68155
6	6	Results of Survival Analysis  (Cox Proportional Hazards Model)  for the Combined End Point: Cardiac Mortality + Urgent Heart Transplantation + Readmission for Congestive Heart Failure	0	16	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-4.9360843	10.798	-45.129963	-31.561972	5.502137
7	7	Impact of Normal Versus Reduced Left Ventricular Ejection Fraction on the Mortality of Congestive Heart Failure Cases: Results of Cox Proportional Hazards Regression Models	0	18	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-7.008701	11.168139	-86.47909	163.13261	40.63826
8	8	Description of the Left Ventricular Ejection Fraction  (LVEF%)  at Different Time Periods: At the Time of Transplant Evaluation, While on the Waiting List to be Transplanted, and During the Follow-Up After Kidney Transplantation	0	18	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-10.108216	8.083006	-78.16305	-120.99602	129.57318
9	9	Univariate Cox Regression Analysis and Cox Proportional Hazards Analysis of Predictors of Cardiac Death legend	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.114168	13.3855915	-101.118744	-85.46591	22.858034
10	10	Gender-Specific Mean and Standard Deviation of LV Mass, End-Diastolic Volume, Stroke Volume, Ejection Fraction, and Cardiac Output by Cardiac MRI in MESA Participants	0	16	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.952719	4.3523765	-122.34666	-63.985104	113.24813
11	11	Results of Multiple Logistic Regression Analysis: Final Significant Variables in Equation Using Forward Stepwise Selection  (Wald)	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-7.775637	8.078746	-77.03149	-56.823425	36.21661
12	12	Multivariable Cox Proportional Regression Analysis Showing Significant Predictors of Outcome  (Death, Heart Transplant, or Left Ventricular Assist Device Implantation)  in Cardiac Resynchronization Therapy Patients	0	15	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-4.2117243	12.431869	-138.55489	-104.98801	54.368935
13	13	Multiple regression analysis using Cox's proportional hazards model to determine the influence of individual variables on survival in hypopituitarism	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.754534	8.689583	-63.93097	-47.221874	72.62056
14	14	ORs and RRs  (95% Confidence Intervals)  for Other Correlates of Preserved Left Ventricular Systolic Function in Order of Entry Into the Full Logistic Model	0	8	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.475136	7.098746	-55.333664	-55.338398	-39.06977
15	15	Multiple Regression Analysis of Variables Associated With CD40L Levels; Entire Model  (Regression Summary for Dependent Variable: R2= 0.60, F = 5.58; p < 0.00005)  and Final Model With Stepwise Method	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.8901114	6.9981484	-91.16577	4.4422965	63.690556
16	16	Final multivariable Cox proportional hazards model of time to first late seizure in the derivation cohort	0	8	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.044251	7.550008	-46.84393	-71.84314	53.98195
17	17	Univariate and Multivariate Linear Model of Left Ventricular End-Diastolic Volume Index in 113 Patients With CHF legend	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-9.087894	3.9023492	-3.5314956	-17.572823	-56.771954
18	18	Logistic Regression Multivariate Independent Predictors of Spontaneous Conversion to Sinus Rhythm	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.1020145	4.5335255	63.985004	-4.353692	23.553669
19	19	Table of Regression Coefficients From a Multivariate Linear Regression Model for LV Mass-to-Volume Ratio	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.236427	5.341943	-95.68234	29.201355	101.35118
20	20	Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of Patients With Chronic Heart Failure at Risk for Cardiac Events	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-3.1726146	10.861912	-30.896452	0.9143864	-9.405141
21	21	Variables Independently Associated With In-Hospital Mortality Adjusted by Risk in a Multivariable Logistic Regression Model and a Multilevel Model, With Odds Ratio and 95% Confidence Intervals for Each Variable	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-1.1997644	7.727975	-85.08579	33.11579	46.94467
22	22	Cox proportional hazards regression model for individual factors affecting graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	0	18	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-29.445906	6.687381	-151.76326	76.66652	54.114773
23	23	Final Multivariable Cox Proportional Hazards Model  (Global Chi-Square of the Model = 1,146.1, p < 0.001)	0	8	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.11585	7.9795265	-40.389214	-46.482613	47.758522
24	24	Multivariate Stepwise Cox Regression Analysis of Potential Risk Variables in Order to Detect Independent Predictors of Cardiac Death or Acute Myocardial Infarction at 30 Days legend	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-4.1689315	14.177957	-101.677605	-78.20323	57.864956
25	25	Intervals Measured During Ventricular Tachycardia, Responses to Pacing During Ventricular Tachycardia and Sinus Rhythm and Presence of Isolated Diastolic Potential During Sinus Rhythm	0	14	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-4.170709	4.453697	29.508915	-79.61914	-167.35968
26	26	Impact of Congestive Heart Failure on Mortality: Results of Multivariable Cox Proportional Hazards Regression Models legend	0	12	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.469717	11.175043	-73.45155	-56.254074	0.7288785
27	27	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients  (Cox Proportional Hazard Model)	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-3.8239863	8.998428	205.93053	-11.24016	-29.379736
28	28	Multiple Linear Regression Analysis Assessing the Independent Influence of Different Variables on Natriuretic Peptides	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-8.2588825	6.998665	-97.730255	62.844162	66.21449
29	29	Multiple Regression Analysis of the Relationship Between Left Ventricular Mass Index and Other Variables for the Entire Group	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-9.603267	6.912652	91.40385	-10.934146	-118.67112
30	30	Cox proportional hazards regression model for graft failure in first-time recipients of kidneys from cardiac-death donors, adjusted for age of donors and recipients, and cold ischaemic time	0	18	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-29.444092	6.678105	161.6113	-82.55007	-53.873905
31	31	Partial Correlation Coefficients  (r) , Controlled for Age, of Body Size, Body Composition and Blood Pressure With Unindexed and Indexed Left Ventricular Mass  (LVM)	0	8	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-8.333586	2.7349308	-26.176954	42.932686	-112.72371
32	32	Multiple Linear Regression Analysis Results With Augmentation Index as the Dependent Variable  a	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-7.925616	6.4039984	-97.163246	-7.8380795	89.27022
33	33	Multivariate Cox Proportional Hazards Regression Model of Significant Predictors of Death or Heart Failure	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.4942923	12.241425	62.329395	-97.182686	3.7291343
34	34	Results of Multivariable Modeling: Hazard Ratios, 95% Confidence Intervals and p Values for Significant Multivariable Predictors of Outcome in Models That Incorporate Echocardiographic, Clinical and Hemodynamic Variables	0	17	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-1.6159729	9.343945	-144.04459	-12.061644	-7.3705726
35	35	Differences Among End-Diastolic Volume, End-Systolic Volume, Ejection Fraction and Left Ventricular Mass as Revealed on Cine MRI and Real-Time MRI legend	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.507626	4.9219913	58.823204	9.810339	-111.67197
36	36	Analysis of Significance and Prognostic Value of End-Diastolic Volume, Stroke Volume, Left Ventricular Ejection Fraction and Heart Rate Obtained During Dobutamine Infusion  a	0	12	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-10.813218	3.9135349	-3.600371	-49.79743	-138.74446
37	37	Multivariate Logistic Regression Analyses to Assess the Predictive Value of Electrocardiographic Strain for the Presence of LVH, Abnormal LV Geometry and Abnormal LV Midwall Function in Patients With and Without Evident CHD    legend	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.633543	-12.937204	-130.0792	53.490166	95.12472
38	38	Final Multivariable Cox Regression Model of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.905689	13.28181	179.56044	34.63687	21.315165
39	39	Multivariable Analysis for Independent Predictors of Survival in HFpEF Patients With CAD  (Cox Proportional Hazard Model)	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-3.5887313	8.953609	-43.484127	-4.543259	33.377583
40	40	Cox proportional hazard analysis for the effect of covariates on survival in patients with chronic heart failure  (SOLVD)	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-3.473796	10.266278	-99.142685	104.934616	53.187023
41	41	Multiple Linear Regression Analysis of Clinical and Hemodynamic Variables and Follow-Up Left Ventricular Ejection Fraction  legend	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-9.478802	5.206301	111.092674	56.33764	84.84553
42	42	Odds Ratios  (With 95% Confidence Intervals)  for Univariate Predictors of Mortality and for Those Same Predictors Together With Log10Troponin in Bivariate Models	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-2.2904613	8.17776	-56.360012	25.118185	39.825577
43	43	Multivariate Cox Proportional Hazards Models for Prediction of Time to Recurrence legend	0	7	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-5.0793924	6.010013	93.12794	-16.029493	26.69914
44	44	Univariate and Multivariate Analysis of Predictive Variables for log Vo 2max/kg2/3	0	5	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.6564956	3.2564151	-27.130457	11.818391	-203.79662
45	45	Cox Proportional Hazard Models for MR-proANP and NT-proBNP to Predict Survival in Different Subgroups of Patients With Chronic Heart Failure  (Derivation and Validation Samples Combined)	0	17	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-2.0806665	11.256072	-10.900024	2.3507655	17.631142
46	46	Computer Directed and Clinically Directed Stepwise Multiple Logistic Regression and Cox Proportion Hazard Analysis of Determinants of Hard Events in Medically Treated Patients legend	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-2.3384786	14.088008	-70.8226	-96.44919	11.293466
47	47	Multivariate analysis of predictors of ventricular tachycardia, sudden death, and atrial flutter/fibrillation after repair of tetralogy of Fallot	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-4.4383817	17.008625	-110.35646	-100.00927	-13.028434
48	48	Unadjusted Cox Proportional Hazards Regression Analysis of Predictors of Death Among 1,953 Children With DCM Not Undergoing Heart Transplantation	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.683807	13.309905	-98.02237	-115.986176	35.625706
49	49	Multivariate Cox Regression Analyses for Peak Vo 2and Ve/Vco 2Slope	0	5	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.2167077	4.1646996	-70.27599	7.441901	112.66986
50	50	Potential effect of the internet on physical activity interventions  (based on effect estimates from web-based physical activity interventions and other physical activity interventions)  and the potential effect of mobile phones on physical activity interventions  (based on effect estimates from telephone-based physical activity interventions and from other physical activity interventions) , by country income	1	36	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-3.6889386	-7.771775	-122.11652	115.494675	-27.914268
51	51	Analysis of trends from 19992002 and 200306 for government health expenditure as source  (GHE-S) ; share of general government expenditure spent on health  (GHE-S/GGE) ; share of gross domestic product  (GDP)  spent by government  (GGE/GDP) ; and GDP	2	18	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-16.318247	10.45656	-122.71435	-48.28543	3.8972278
52	52	Changes between 2012 and 2017 in the modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, demand satisfied with modern methods, and the number of women of reproductive age who are married or in a union using modern methods of contraception	1	22	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-22.34634	-9.677414	109.938965	41.841908	-46.505783
53	53	Postprandial Changes of Nitrates/Nitrites, Lipoperoxides, and 8-epi Prostaglandin Plasma Levels After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	1	17	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-1.4258217	23.210985	177.25858	5.09208	-51.18867
54	54	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of two analytical approaches by high-focus, northeast, and non-high-focus states	1	16	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-6.1432605	22.193052	134.02045	-62.762886	78.43439
55	55	Number  (millions)  of women with an unmet need for modern methods and proportion of those wanting to avoid pregnancy with unmet need for modern methods, by region and subregion and by country income, in 2003, 2008, and 2012	1	19	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-18.717627	-10.343411	-89.80011	10.221405	-105.15759
56	56	Aggregate official development assistance to maternal, newborn, and child health, to child health per child, and to maternal and newborn health per livebirth in 2005 and 2006, and percentage change for the two categories between 2003 and 2006	2	16	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-9.970469	-20.330833	-9.175517	149.58716	-41.219048
57	57	Official development assistance to child health per child and to maternal and neonatal health per livebirth, total to maternal, newborn, and child health in 2007 and 2008, and trends statistics, 200308	2	16	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-9.950315	-20.313982	-9.206759	-174.9349	-4.401752
58	58	Official development assistance to maternal, newborn, and child health by aid modality and project purpose for the 68 Countdown priority countries, 200308	2	13	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-7.128037	-17.179092	-88.711105	56.058582	-40.104824
59	59	Official development assistance to maternal, newborn, and child health to the 74 Countdown priority countries by type of aid and purpose of projects between 2003 and 2010	2	13	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-8.983381	-17.44237	-45.80148	38.527485	-39.62648
60	60	Effects of varying selected assumptions on the estimated additional annual running costs of providing child survival interventions at universal coverage, from reported levels in 2000  (US$5134 million)	1	18	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-12.262004	21.478449	-143.4692	85.88603	-0.57752365
61	61	Time-series cross-sectional regression results for government health expenditure as source  (GHE-S)  as a share of gross domestic product  (GDP)  for countries in Global Burden of Disease developing regions based on the Arellano-Bover/Blundell-Bond model	2	19	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-15.621796	10.245414	-103.85306	-31.66186	15.44229
62	62	Modern contraceptive prevalence rate  (mCPR) , unmet need for modern methods, and demand satisfied with modern methods in 2017 for 68 Family Planning 2020 countries	1	16	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-22.204554	-9.598082	-145.43246	-41.814606	-41.36278
63	63	Numbers and incident rate ratios for recorded referrals and identifications of women experiencing domestic violence in general practice and domestic violence referrals received by specialist agencies, 12 months after intervention	1	14	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-7.151294	-6.6942773	-9.105982	77.112015	-134.82596
64	64	Number  (millions)  of women using modern methods and proportion of those wanting to avoid pregnancy using modern methods, by region and subregion and by country income in 2003, 2008, and 2012	1	15	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-18.166206	-10.482058	-69.118004	18.824074	-97.17324
65	65	Estimated annual running costs of providing preventive interventions for child survival at 2000 coverage levels and universal coverage levels	1	14	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-11.608531	22.102917	-140.04144	68.72096	-24.301994
66	66	Antipneumococcal IgG antibody responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	3.857635	29.266792	88.43638	61.848515	-0.17685564
67	67	Official development assistance to maternal, newborn, and child health by type and source of aid flow for the 68 Countdown priority countries, 200308	2	13	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-7.600252	-16.926933	-63.678463	66.86179	-39.753742
68	68	Health service resource use: mean  (SD)  resource use per patient and unit costs of resource items by type of care  (UK, 2009 prices)	1	11	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-20.157446	8.3972	-150.22163	42.708027	-102.45335
69	69	Antibodies to neuronal antigens in cerebellar syndromes   Sera were screened by routine immunohistochemistry on frozen sections of rat cerebellum and positive staining patterns1 were confirmed, as appropriate, by western blotting on rat cerebellar extracts or recombinant Hu or Yo polypeptides. VGCC antibodies were measured by immunoprecipitation of 125I--conotoxin MVIIC-labelled VGCCs extracted from human cerebellum,  2   and antibodies to glutamic acid decarboxylase measured with a commercial kit  (RSR Ltd, Cardiff, UK) .	3	30	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-9.640298	-3.1793995	9.3699875	-73.208496	-16.450642
70	70	Direct health-care costs attributable to physical inactivity paid by the public sector, private sector, and households, by country and WHO region  (in 1000 Int$, 2013)	1	15	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-4.605499	-16.005486	-93.15508	80.127716	-7.192685
71	71	Ranking of research priorities for development of interventions to reduce stillbirths in low-income and middle-income countries	1	11	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-2.4193132	5.751489	-88.69193	-39.82589	-58.5455
72	72	Rankings of research priorities for implementation of interventions to reduce stillbirths in low-income and middle-income countries by 2015	1	11	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-2.4173129	5.750868	-69.81247	-18.13006	-52.487083
73	73	Worldwide official development assistance to maternal, newborn, and child health by type of aid and purpose of projects between 2003 and 2006	2	11	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-9.316451	-17.037043	-64.54171	27.09775	-51.646194
74	74	Official development assistance to reproductive health to the 74 Countdown priority countries by type of aid and purpose of projects, 200910	2	11	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-8.462669	-17.909378	-59.162968	43.327297	-16.513716
75	75	OPA responses 1 month after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	3.0273414	28.727253	61.69524	69.428604	-8.044323
76	76	Estimated number of neonatal deaths in 75 countries by region that could be averted by universal  (99% coverage)  delivery of all  *   evidence-based interventions	1	8	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-8.46826	16.316032	-96.73862	101.74898	-61.573177
77	77	Percentage distribution of women in developing countries using modern contraceptives, by type of method, region and subregion, and country income, in 2003, 2008, and 2012	1	12	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-17.376455	-10.565131	-48.244446	12.678213	-83.956825
78	78	Antipneumococcal IgG antibody responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	15	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	3.44788	30.02101	49.966095	42.46228	3.094021
79	79	Estimated annual running costs of delivering treatment interventions for child survival at 2000 coverage levels and universal coverage levels	1	14	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-11.555593	22.155842	107.99626	66.506195	132.36493
80	80	Neglected low-cost opportunities and high-cost interventions in south Asia and sub-Saharan Africa	1	10	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-4.9311576	-2.9128034	55.274387	59.50586	-64.56097
81	81	Estimates and uncertainty intervals of the number of MWRA  (millions)  aged 1549 years, for total contraceptive use, unmet need, total demand, and unmet need for modern methods, for 2010 and 2015	1	14	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-20.279984	-9.281376	-117.94278	11.219387	-125.814186
82	82	Serum-antibody concentrations against capsular polysaccharide of Haemophilus influenzae type b  (PRP)  in Chilean infants given different primary immunisation regimens of PRP-T and PRP-CRM197 conjugate vaccines	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	-18.44602	14.035106	-187.79268	13.720492	45.902847
83	83	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively low serum total IgE  (n=67)	1	16	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	8.303416	-25.18513	104.63407	-56.318504	-31.273006
84	84	Official development assistance to maternal, newborn, and child health by donor for the 68 Countdown priority countries, 200308	2	11	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-6.9056473	-16.780947	-77.61747	63.03969	-62.19518
85	85	Change in numbers of sexual partners and prevalence of sexual practices, behaviours, and attitudes in Natsal-3 and Natsal-1 relative to Natsal-2, by sex	1	13	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	7.485502	-1.0129279	-11.264516	8.495262	-84.0246
86	86	Birthweights of children born to mothers with chronic pregnancy-associated P falciparum malariaaccording to mothers' plasma IgG concentration with specificity for type of VSA	1	13	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	4.541422	8.813478	-42.115303	-159.68008	98.952194
87	87	Estimated odds ratios for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children without BHR but with relatively high serum total IgE  (n=104)	1	17	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	8.821852	-25.174652	110.958046	-81.17916	-21.178368
88	88	AUC of the Different Parameters After the Ingestion of a Phenol-Rich Olive Oil Meal  (400 ppm)  as Compared to a Low Phenol Olive Oil Meal  (80 ppm)	1	10	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-1.4263622	23.208746	-192.33316	-16.728437	-25.22084
89	89	Estimated preterm birth rates and total number of preterm births for 2010, by Millennium Development Goal region	1	7	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-5.56731	2.7345572	-35.4248	60.18192	-74.48105
90	90	Serum concentrations of antibodies against individual pneumococcal vaccine serotypes and protein D one month after the third protein D conjugate vaccine dose and before and 1 month after booster vaccination*	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	-5.6759386	-5.0107455	98.577225	126.56335	-87.43156
91	91	Estimated odds ratios  (95% CI)  for prevalence of respiratory symptoms and decrease in peak expiratory flow  (PEF)  with increase in air pollutants in children with BHR and relatively high serum total IgE  (n=121)	1	16	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	8.430743	-25.182436	73.5172	174.5977	10.135811
92	92	Antibody responses after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	2.8439333	29.923397	65.198105	57.83835	22.521442
93	93	Percentage of ever-partnered women reporting selected symptoms of ill health  *   according to experience of physical or sexual violence, or both, by an intimate partner, by site	1	10	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-0.015853517	12.865604	-10.98831	-65.79311	131.24686
94	94	Median price ratios  *   of originator brands and lowest-priced generics in the private sector, and of lowest-priced generics in the public sector, by WHO Region	1	16	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-3.7067845	-15.69086	-98.59493	71.39787	20.664825
95	95	Antibody responses after booster vaccination with PHiD-CV and DTPa-HBV-IPV/Hib with or without prophylactic antipyretic administration  (ATP immunogenicity cohort)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	3.7587302	28.530935	73.57756	46.11764	-20.729568
96	96	Comparison of mean adjusted death rate, mean number of acute-care hospital beds, mean number of surgeons, and mean total Medicare-enrollee reimbursements by regions of high, middle, and low adjusted surgical intensity at the end of life	1	10	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-4.9097195	18.03959	-94.681786	-80.62907	-30.800467
97	97	OPA responses 1 month after primary vaccination with PHiD-CV, DTPa-HBV-IPV/Hib, and human rotavirus vaccine with or without prophylactic administration of paracetamol  (ATP immunogenicity cohort)	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	2.518345	29.42396	76.65376	34.530285	10.124756
98	98	Proportion of women with polycystic ovaries, mother's weight, body-mass index, and mean concentrations of plasma LH and testosterone according to birthweight among women whose mothers' weight in pregnancy was above 58 kg  (median)	1	17	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-15.48258	-7.3254523	11.699935	-168.03845	101.66771
99	99	Analysis of association between receipt of financial assistance from Janani Suraksha Yojana and intervention coverage and health outcomes by use of three analytical approaches at the national level	1	13	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-6.1369715	22.156073	-126.659134	-76.70501	-106.591255
100	100	Treatment efficacy at week 36 for the modified intention-to-treat population in the open-label period and at week 88 for the modified intention-to-treat subpopulations in the double-blind period	6	17	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	15.731921	-5.336514	-20.503754	91.20297	77.056465
101	101	Overview of treatment-emergent adverse events grade 12  (occurring in 10% of patients) , all grade 3 and worse adverse events, and all serious adverse events	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.384136	-14.793227	-109.3294	26.365562	-67.051926
102	102	Most common adverse events, grade 3 or worse adverse events, and serious adverse events during the overall treatment period  (neoadjuvant and adjuvant)	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.021725	-14.329724	69.0964	60.725006	76.18944
103	103	Drug-related adverse events occurring at any grade in at least 10% of patients, or at grade 3 or higher in any patients in either group, from the start of treatment to 30 days after the end of treatment  (safety population)	6	17	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	25.897726	-9.455595	83.055626	-4.09109	176.20515
104	104	Drug-related treatment-emergent adverse events by MedDRA system organ class and preferred term in the first on-study chemotherapy cycle  (safety population)	6	16	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.371172	-9.655835	9.859159	0.6873564	97.62503
105	105	Treatment-emergent adverse events and treatment-emergent drug-related adverse events  *    (safety population)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	18.789305	-10.657232	49.793015	-26.60017	124.362114
106	106	Adverse events  (any grade)  experienced by 15% or more of patients in either treatment group, and CTCAE grade 3 or higher events occurring in 3% or more of patients in either group	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	24.930779	-11.522739	112.48645	-16.704863	123.320625
107	107	MedDRA Summary of Treatment Emergent Adverse Events Occurring in >3% in Either Treatment Group by Primary System Organ Class and Preferred Term: All Subjects Population	6	16	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	20.87013	-9.97698	9.813195	-9.171764	128.64534
108	108	Safety endpoints and treatment-emergent adverse events of special interest, by treatment assignment over weeks 010  (study part 1)  and weeks 1020  (study part 2)	6	13	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	17.62924	-7.5657487	75.3106	93.03534	152.97388
109	109	Treatment-emergent adverse events possibly or probably related to treatment in at least 1% of patients  (intention-to-treat population)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	15.255625	-9.479251	147.83746	26.909006	62.760483
110	110	Treatment-emergent adverse events occurring in 10% or more of patients in either group during the double-blind period  (safety population)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.425976	-8.373312	-16.066105	-48.25427	-203.21251
111	111	Treatment-emergent adverse events in every treatment group during the 12-week treatment period  (safety population)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	20.710054	-8.495649	59.06308	-16.63351	97.054756
112	112	Grade 12 adverse events occurring in 10% or more of patients and all grade 35 adverse events in the fulvestrant plus palbociclib safety population  (all causalities and all cycles)	6	15	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.955017	-15.671825	16.274624	95.045616	131.82407
113	113	Treatment-emergent adverse events reported by 2% of patients in either treatment group during the double-blind maintenance period	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	21.64222	-8.168261	-170.01057	-5.77159	-68.66333
114	114	Overall Incidence of AEs, Discontinuations Due to AEs, and AEs Occurring in 2% of Patients During the Double-Blind Treatment Period  (Safety Population, n = 672)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	21.712114	-5.457813	-32.50501	-25.190968	140.52144
115	115	Recurrence-free survival, distant metastasis-free survival, and overall survival in the intention-to-treat population	2	7	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	13.711608	-5.6803226	-55.94425	65.74721	154.5014
116	116	All serious adverse events, adverse events occurring in 10% or more of patients in any treatment group, and adverse events of special interest	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.51366	-11.974906	110.90118	82.69936	-130.7354
117	117	Most common adverse events leading to everolimus and exemestane discontinuation, dose adjustment, or dose interruption, with suspected relation to everolimus  (safety population, n=92)	6	9	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	15.7666235	-11.989625	106.57012	114.7646	71.61719
118	118	Adverse events  *   of more than 2% difference between treatment groups  (for all grade adverse events)  and adverse events of CTC grade 3  (EFS population)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	21.222431	-15.055368	0.39527524	56.891327	110.22027
119	119	Serious adverse events and most common adverse events related or possibly related to treatment  (ITT population)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	18.283895	-12.861339	141.92657	-30.904722	-121.84751
120	120	Treatment-related adverse events of any grade reported in at least 10% of patients and all grade 34 events in 78 patients who received nivolumab	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	23.789055	-13.2240925	33.497406	65.51306	150.42302
121	121	Treatment-emergent adverse events group in all participants who received 1 dose of study drug  (occurring in 5% in either treatment)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.101933	-10.020202	35.20773	-5.669311	152.6314
122	122	Treatment-emergent adverse events, irrespective of association with study drug, by preferred term  *   and treatment  (safety set)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	18.386278	-8.839728	22.193304	-41.827312	124.96153
123	123	Most common adverse events by treatment group, reported by 15% of patients at any grade or by 3% of patients at grade 3 severity  (safety population)   *	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	26.96598	-11.76315	-7.8885508	49.354534	162.704
124	124	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events; NCI CTCAE 3.0)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.0437	-13.5487995	56.03186	57.533962	119.283966
125	125	Treatment-related select adverse events and treatment-related adverse events leading to discontinuation of both study drugs	6	13	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	18.15203	-12.053173	32.170002	33.158348	86.77003
126	126	Summary of total adverse events and treatment-related adverse events through week 96 in the safety maintenance population	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.458252	-11.475023	43.927242	11.760109	111.540565
127	127	Grade 3 or 4 and serious adverse events and reactions, and adverse events leading to quinacrine discontinuation or dose reduction	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	17.827103	-14.925011	82.41613	86.831566	63.092514
128	128	Overall survival in all randomly allocated patients who received at least one dose of study treatment in the intention-to-treat population	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	14.749026	-6.1979847	90.86415	-139.38945	68.88615
129	129	Adverse events reported by 10% or more patients for grades 1 and 2 and all adverse events for grades 35  (safety population)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.567532	-16.183441	43.63498	125.25083	133.00552
130	130	Adverse events of 10% incidence in either treatment group or grade 3, 4 adverse events of 05% incidence in either treatment group  (safety set)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	23.737429	-10.753419	107.45141	18.62876	142.17471
131	131	Drug-related adverse events  (10% of patients in either treatment group with grade 12 and all grade 3 adverse events) .	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.025354	-13.53516	33.745667	62.96923	115.86223
132	132	Grade 3 and 4 adverse events  *   experienced by 2% or more of patients and adverse events leading to treatment discontinuation, after randomisation to rituximab maintenance or observation	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	17.506502	-15.183102	36.388638	153.3391	-129.63104
133	133	Common adverse events  (10% in either treatment group)  reported up to 28 days after study drug discontinuation  (safety population)	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	17.173506	-10.278256	82.62313	22.36297	101.41083
134	134	Treatment-emergent adverse events  (MedDRA HLT or PT)  occurring in 5% or more of patients in the placebo or combined dupilumab doses groups  *	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	15.339627	-13.957466	92.32978	-52.668304	110.59552
135	135	Overview of incidence of treatment-emergent adverse events by treatment at adverse event onset by system organ class	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.415283	-8.136845	-8.5559435	20.302864	138.3753
136	136	Overall incidence of treatment-emergent adverse events occurring in 10% or more of patients who received one or more doses of study drug	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	23.953373	-7.2853327	91.17619	-54.624203	142.28943
137	137	Overview of adverse events, classified by Common Terminology Criteria for Adverse Events  (version 3.0)  in all patients who received at least one dose of study drug	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	25.031822	-14.079589	30.872442	31.1612	146.81639
138	138	Incidence of grade 35 adverse events occurring in 2% or more of patients given chemotherapy with or without bevacizumab after disease progression following first-line bevacizumab-based treatment  (safety population  *  )	6	16	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	24.850536	-6.432161	120.91018	-72.03673	132.17249
139	139	Treatment-emergent adverse events leading to discontinuation of treatment  (intention-to-treat population)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	15.871095	-9.316743	-59.98367	0.81754726	-178.15077
140	140	Virological response over time  (RVR and SVR12) , and on-treatment failure and relapse, according to treatment group in the intention-to-treat population	6	9	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	14.469478	-8.172832	18.115814	71.257256	13.652163
141	141	Most common  (10%)  treatment-emergent adverse events by study group and preferred term  (safety population)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	18.309153	-9.483959	-136.36855	-51.329628	68.131805
142	142	Overview of treatment-emergent adverse events  (MedDRA preferred terms)  and injection-site reactions  (MeDRA high-level terms)  in the safety population	6	15	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.516407	-6.36828	21.525131	-33.378548	83.32606
143	143	Treatment-emergent adverse events leading to discontinuation of study drug in the safety population  (n=2485)	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	16.963146	-9.42707	-19.112446	-122.23673	64.934586
144	144	Patients with any adverse event and with grade 34 adverse events related to study treatment  (2-weekly regimen)	6	11	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	19.927052	-12.968012	30.739368	66.362885	81.15822
145	145	Incidence of prespecified treatment-emergent adverse events  (preferred terms)  during the double-blind period  (safety population, n=515)	6	13	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	20.581484	-7.0061865	44.612988	-48.616154	94.673386
146	146	Serious adverse events in any treatment group and treatment-emergent adverse events occurring in 5% or more of patients	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	22.254135	-11.245609	145.32265	-9.427961	241.6535
147	147	Treatment-emergent adverse events of any grade reported in at least 10% of patients in either group in the safety population	6	10	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	23.461588	-9.553906	130.67664	64.21863	46.82454
148	148	Proportion of participants experiencing at least one grade 35 adverse event by 52 weeks that was possibly, probably, or definitely related to study treatment using a modified intention-to-treat analysis for a model based on the raw dataset and imputed dataset	6	14	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	13.95756	-10.100661	-22.138319	-33.75398	94.74374
149	149	Treatment-related adverse events occurring in 5% of patients in either group from start of treatment to 30 days after end of treatment  (safety population)   *	6	13	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	24.517033	-9.131006	72.78032	6.3463006	143.84859
150	150	Early Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Use in Patients Managed With Early Invasive Strategy  (Cath 48 h From Admission)  Versus Conservative Care  (Cath >48 h After Admission or No Cath)	7	17	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-17.766079	-5.9790626	138.57277	12.578001	-58.285927
151	151	Patients With Standardized Criteria for Urgent and Elective Coronary Angiogram, and Rates of Urgent PTCA and CABG Among These Patients During the 28 Days Following Onset of Unstable Angina, by Type of Hospital	7	18	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.9016318	-7.3633914	-0.14214234	-95.13827	-49.856544
152	152	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups Following Matching by Propensity Analysis	7	15	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.2901318	-4.738881	15.242343	-52.256626	-49.65364
153	153	A Summary of Time Frames of PTCA, Surgery, Antiplatelet Therapy and Complications in Patients Who Experienced Major Complications After Noncardiac Surgery Preceded by Intracoronary Stent Placement legend	7	19	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	1.567885	-7.5562105	91.21826	-149.08386	-82.25936
154	154	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Cardiac Electrophysiologic Parameters in Postinfarction Dogs legend	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-29.906082	-7.4741883	78.19422	-40.900597	3.1316981
155	155	Plasma Renin Activities in Postinfarction Dogs Administered Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle legend	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-29.648157	-7.7327437	80.08051	116.64449	-5.209282
156	156	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on the Incidence of Lethal Ischemic Arrhythmias Developing in Response to Secondary Acute Posterolateral Myocardial Ischemia in Postinfarction Dogs	7	15	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-30.497917	-7.2598324	70.036194	105.047775	20.799973
157	157	Initial Procedural Outcome  (Among 608 CABG and PTCA Patients With IR Intended and 579 PTCA Patients With CR Intended if Randomized to PTCA Who Received Their Assigned Treatment)  legend	7	14	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	9.112989	-10.128406	30.44857	87.267746	50.724052
158	158	Ischemic and Bleeding Outcomes 12 to 30 Months After Coronary Stent Treatment in all Randomized Patients, Stratified by Presentation With Versus Without Acute Myocardial Infarction	7	13	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	6.4759355	-5.419189	-162.59679	22.038136	-0.62028563
159	159	Death, MI, or Refractory Ischemia or Major Bleeding in Patients Undergoing PCI by Loading Dose of Clopidogrel or Type of GP IIb/IIIa Inhibitor	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.993797	0.6895104	84.23266	-79.45998	77.20969
160	160	Procedures, Complications and Clinical Outcomes of Patients at Hospital Discharge in Invasive and Conservative Therapy Groups *	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.4309819	-4.5303674	40.698658	-32.40849	41.44842
161	161	Effect of Intravenous Losartan  (1.0 mg/kg + 0.03 mg/kg/min) , EXP3174  (0.1 mg/kg + 0.01 mg/kg/min) , Captopril  (1.0 mg/kg + 0.5 mg/kg/h)  or Vehicle on Sinus Heart Rate, Mean Arterial Pressure and Electrocardiographic Intervals in Postinfarction Dogs legend	7	8	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-29.627047	-7.039362	68.5418	-59.546192	-13.1259165
162	162	Intraoperative and Postoperative Complications for Patients Undergoing Off-Pump and On-Pump CABG Surgery in New York State, 19972000	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-2.744692	-4.0531287	90.70965	38.360935	-86.302795
163	163	Risk of THV Thrombosis in Relation to Post-TAVR Antithrombotic Therapy Until 1- to 3-Month Post-TAVR Follow-Up  (Routine Follow-Up Visit 1)	7	9	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	9.186166	-7.364352	137.64139	-112.36495	74.80035
164	164	Death, MI, Refractory Ischemia, Major Bleeding, and Net Clinical Outcome at 30 Days in Those Treated With a GP IIb/IIIa Inhibitor	7	9	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.4776993	-0.4378496	81.25434	-51.11179	59.23704
165	165	In-Hospital Course of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	2.5345924	0.48146516	12.784568	-41.237083	15.672969
166	166	Sensitivity analysis and 1-year mortality in all patients and in patients who survived until day 14, day 30, day 60, and day 90 after acute myocardial infarction  (AMI)	7	7	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-0.11900713	-2.8979769	54.032253	-43.72356	-46.949116
167	167	Mortality Over Time Among All Patients in PCI Studies Randomizing Patients to Standard Therapy or Standard Therapy Plus Abciximab With a 12-h Infusion After PCI  (Excludes Patients Not Randomized to a Common Intervention [EPISTENT PTCA/Abciximab Group])  legend	7	17	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	14.814083	9.425834	133.8273	-33.043793	36.847404
168	168	Community Hospital Complications of Patients With Acute Myocardial Infarction and Cardiogenic Shock Treated With or Without Intraaortic Balloon Counterpulsation	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	2.592764	0.56047565	11.985469	-63.267982	19.304905
169	169	Neurological presentations of 424 patients with gluten sensitivity, who presented with neurological dysfunction and were seen in the gluten sensitivity/neurology clinic, in Sheffield, UK, from 1994 to 2009	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	3.783334	-6.325529	123.679245	-126.87501	3.590266
170	170	Revascularization Procedures in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  or Conservative  (CON)  Management Strategies legend	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	5.8437963	-8.484231	100.401634	-16.270203	-46.846493
171	171	Early and Late Outcomes of Hospital Survivors of AMI and Cardiogenic Shock According To Myocardial Infarction Type	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	1.440748	-2.6451678	-27.287973	1.8269507	-122.57933
172	172	In-Hospital Outcomes of Elderly Patients  (65 years old)  With or Without Previous Angina 48 Hours Before Acute Myocardial Infarction	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	2.0162597	-0.4837912	43.998768	-61.24717	18.729021
173	173	Clinical Outcomes at 30 Days According to Consistent Therapy on Enoxaparin Versus Switch From Enoxaparin to Bivalirudin	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.638501	-2.4776108	96.73297	26.957811	48.63157
174	174	Clinical Outcomes Stratified by Stent Type and Peri-Procedure Administration of Platelet Glycoprotein IIb/IIIa Inhibitors	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-2.018509	-2.6598952	-25.662497	71.08343	-22.01502
175	175	In-Hospital Bleeding Complications of Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	7	12	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	2.8188758	-2.3756042	-132.95894	27.206549	55.781895
176	176	Comparison of Admitting Diagnosis and Initial Hospital Bed Assignments of 29,585 Patients With LBBB and Acute MI in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend	7	13	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.3893514	-16.245417	32.825054	-122.662865	-60.543823
177	177	30-Day and Long-Term Reinfarction According to Degree of ST-Segment Resolution at 90 Min and 4 Hours After Initiation of Reperfusion Therapy	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	2.3434038	-3.6662588	-16.089058	-34.902718	-98.629944
178	178	Comparison of Treatments Received by 29,585 Patients With Acute MI and LBBB With and Without Chest Pain in the National Registry for Myocardial Infarction 2  (June 1, 1994March 31, 1998)  legend legend	7	13	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.400917	-16.25655	-177.28894	57.017445	14.405094
179	179	Clinical Outcomes at Day 9 in Patients Undergoing Early PCI  (Within 24 h of Randomization)	7	6	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-0.97594035	-1.0585123	-121.35381	-4.7369046	35.584732
180	180	Serial Electrocardiographic Changes in Patients With Suspected Acute Myocardial Infarction Who Were Not Receive Randomized to Prehospital Versus In-Hospital Thrombolysis	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	4.145044	-4.4519134	118.02296	-91.683395	33.55054
181	181	Clinical Outcomes at 30 Days in Patients With ST Segment Elevation Myocardial Infarction According to Thrombolytic and Antithrombin Therapy	7	12	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	3.397342	-2.3841028	113.31101	-68.60196	-67.25158
182	182	Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With>12 Months Versus12Months of Clopidogrel After IndexPercutaneous Coronary Revascularization With BMS	7	11	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-9.67336	13.842862	30.23211	-123.19375	-15.557935
183	183	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Adjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)   a	7	14	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	16.82066	13.81729	-1.4479328	188.18184	-14.952301
184	184	Protective Role of Angina 48 Hours Before Acute Myocardial Infarction in Adult and Elderly Patients: Unadjusted Regression Model for In-Hospital Death and Congestive Heart Failure or Shock and Combined End Points  (in-hospital death, congestive heart failure or shock)	0	13	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	16.820433	13.823729	3.15277	-139.27866	25.245304
185	185	In-Hospital Clinical Outcomes of Patients Undergoing Isolated Tricuspid Valve Surgery From 2004 to 2013  (Unweighted)	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-0.18067451	-1.083036	-147.40321	-15.092957	37.727856
186	186	Short-Term and Long-Term Major Adverse Clinical Events in PCI Patients	6	5	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	-1.9879229	-1.5303597	113.39291	-32.27322	-84.61729
187	187	Early and Systematic Versus Guided or Delayed PCI  (Stent Era and Balloon Era)  After Fibrinolysis for STEMI	7	7	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-7.225066	-4.040044	86.40646	83.81825	-46.140564
188	188	Effect of Surgery on Exercise Parameters in Patients Undergoing Mitral Valve Replacement and Patients Undergoing Mitral Valve Repair legend	7	8	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	0.059862714	-6.2494245	121.58515	10.663156	-97.420105
189	189	Individual Event Rates  (Event/Month)  and Therapy Episodes  (Episode/Month)  of Patients Pre- and Post-CRT Implantation	7	5	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-4.532009	-4.7973585	85.99671	95.70261	-90.150826
190	190	Complications of Thrombolytic Therapy of Prosthetic Valve Thrombosis in 107 Patients	7	7	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-2.158061	1.0646389	-223.42194	-133.2908	-29.851973
191	191	Clinical Outcomes in Surgically and Nonsurgically Treated Patients After Acute Myocardial Infarction	7	9	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.0890207	-2.2176588	-107.818665	14.825192	16.79361
192	192	Effects of aspirin on bleeding episodes and related complications in elective-arthroplasty patients up to day 35	7	4	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.0616726	0.24462532	27.43049	-34.81499	-18.126091
193	193	Hierarchical Incidence of MACE During Hospitalization and 12-Month Follow-Up in Patients With Successful Recanalization of a CTO	7	5	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-1.3045627	1.7466993	-281.12137	53.331493	93.29919
194	194	1-Year Clinical Outcomes in Patients With In-Hospital Versus Out-of-Hospital Definite/Probable Stent Thrombosis	7	8	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	0.63648325	-0.75634366	87.157906	-74.45631	27.022549
195	195	30-Day and 1-Year Event Rates According to the Occurrence of Major VC Versus No Major VC Up to 30 Days	3	5	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	5.6764665	-2.5984035	119.20646	21.200075	27.45817
196	196	In-Hospital Invasive Coronary Procedures, Medications, Complications and Mortality of Patients Treated or Not Treated by Acute Reperfusion legend	7	13	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	0.07874234	-4.3727603	41.149162	-81.0798	-35.395752
197	197	Ischemic and Bleeding Outcomes in all Randomized Patients, According to Acute Myocardial Infarction Status, From12 to 30 Months After Coronary Stent Treatment	7	12	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	6.503763	-5.3859425	81.92955	-9.429247	66.15974
198	198	Reported Cause of Death and Procedures Performed in Post-Lytic NQMI Patients Randomized to Invasive  (INV)  and Conservative  (CON)  Management Strategies legend	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	5.803679	-8.53443	39.011425	-5.851389	-42.85791
199	199	Study Endpoints in Matched Patients: Admission Rate, Length of Stay, MACE, Additional Patient Follow-Up, and Downstream Resource Utilization With CCTA Versus Standard Evaluation  (Both, n= 894)	7	14	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-0.6440815	2.2768857	130.40392	-123.67694	-50.015175
200	200	5-year relative survival  (%)  by use of state-specific and race-specific life tables and age-standardised to ICSS weights  *   with 95% CIs     for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999, by ra US populations	2	18	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-24.09871	18.291857	-79.20893	34.128937	-149.22557
201	201	Decomposition analysis of the change of global disability-adjusted life years  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific disability-adjusted-life-year rates	4	26	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	14.036594	22.548357	-67.16697	10.482836	8.824881
202	202	Global all-age attributable deaths and DALYs, in 2006 and 2016, and percentage change of deaths, age-standardised death rates, DALYs, and age-standardised DALY rates between 2006 and 2016, for all risk-outcome pairs, both sexes combined	4	19	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	16.406788	2.1260738	30.763357	95.47661	-146.71463
203	203	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in England from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in England from 1971 to 2011 by sex	2	17	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	22.510601	1.8884553	138.16118	46.408375	-7.653415
204	204	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of eight common malignancies  (oesophagus, stomach, colon, rectum, liver, pancreas, lung, or melanoma of the skin)  by continent, country, and calendar period of diagnosis	2	22	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-24.271555	14.704968	-51.22767	155.92427	-63.695415
205	205	40-year trends in the index of net survival for all cancers combined at 1, 5, and 10 years after diagnosis in adults  (1599 years)  in Wales from 1971 to 2011 and trends in the age-adjusted net survival for 21 selected cancers in Wales from 1971 to 2011 by sex	2	17	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	22.510328	1.8885581	35.0248	102.94304	-8.647019
206	206	5-year relative survival  (%) , age-standardised to ICSS weights  *   with 95% CIs for adults  (aged 1599 years)  diagnosed with cancer of the breast  (women) , colon, rectum, or prostate during 199094 and followed up to Dec 31, 1999: continent, country, and region	2	20	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-24.099724	18.249311	-59.458286	42.51483	-155.19217
207	207	Age-adjusted annual incidence and mortality rates  (per 100000 person-years) , disability-adjusted life-years  (DALYs)  lost, prevalence  (per 100000 people) , and mortality-to-incidence ratio  (MIR)  by age groups in high-income and low-income and middle-income countries, and globally in 1990, 2005, and 2010	4	14	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	17.103819	5.399654	-23.876204	102.014824	-100.961296
208	208	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in childhood and adolescence, stratified by type of cancer of index patient	2	18	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	1.5555099	19.377306	-136.96326	131.3982	14.365834
209	209	Male dose-related excess mortality in ever-drinkers as a proportion of all mortality in male ever-drinkers and never-drinkers, by age and underlying cause of death	4	14	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	8.751585	-13.919307	-77.9386	-64.340195	-89.05675
210	210	Female dose-related excess mortality in ever-drinkers as a proportion of all mortality in female ever-drinkers and never-drinkers, by age and underlying cause of death	4	14	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	8.753288	-13.919286	8.87072	-179.18027	44.61371
211	211	Top 10 causes of disability-adjusted life-years  (DALYs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	18.6595	6.4442377	-135.3073	92.418594	-76.080795
212	212	Age-standardised and sex-standardised mortality ratios of all-cause, suicide-related, and cancer-related mortality in patients with chronic fatigue syndrome, compared with the general population in England and Wales in 2011	4	9	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	3.3071854	-9.440202	10.47887	40.710274	-75.93729
213	213	5-year age-standardised net survival for adults  (aged 1599 years)  diagnosed with one of ten common malignant diseases and children  (aged 014 years)  with ALL, by continent, country, and calendar period of diagnosis	2	18	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-24.369019	14.676171	-31.868237	53.83352	42.79509
214	214	Global life expectancy at birth and at age 50, age-standardised death rates, age-standardised YLL rate, and total deaths, by sex, 19802015	4	11	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	13.936767	4.303205	39.462704	105.9956	-86.39995
215	215	Observed and expected deaths from breast cancer in the initial cohort within 16 years and rate ratios  (intervention centres vs combined comparison centres)  for cases diagnosed within 7 and 10 years of date of entry	2	13	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	9.127097	-18.83119	77.015495	143.47073	42.439285
216	216	Life years lost and excess life years lost by cause of death in people with and without mental disorders	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-3.5745246	-2.5835881	-1.403676	99.710724	-46.165565
217	217	Adjusted hazard ratios  (HRs)  for mortality in relation to childhood BMI and BMI change during puberty for 37672 Swedish men followed for a mean of 378 years after age 20 years	4	10	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	5.09381	12.302799	-90.6957	128.79349	-103.067444
218	218	Standardised incidence ratios  (SIRs)  for nervous-system tumour types subdivided by age at diagnosis in offspring with a sibling diagnosed with any nervous-system tumour	2	14	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	7.0031133	1.4936396	58.988976	57.31606	-118.66436
219	219	Male relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	4	20	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	22.208515	11.5682955	-16.674118	12.938741	-170.26782
220	220	Unadjusted and Adjusted Association of Heart Rate Variability Variables With All-Cause Mortality, Cardiac Mortality, Sudden Cardiac Mortality, Sudden Cardiac Autopsy-Verified Mortality, Sudden Cardiac Mortality for Both Genders, Nonsudden Cardiac Mortality and Nonsudden Cardiac Mortality With Cerebrovascular Mortality legend legend	0	33	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	2.6294682	15.165776	-75.2979	-25.715183	-16.899815
221	221	Observed  (O)  and expected  (E)  numbers of cancers, standardised incidence ratio  (SIR)  with 95% CI for colorectal cancer in first-degree relatives of patients with either ulcerative colitis or Crohn's disease in Sweden 195595	2	14	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	6.046959	3.1531432	23.311121	30.575941	-119.04827
222	222	Global deaths, age-standardised death rates per 100000, YLL numbers, and age-standardised YLL rates per 100000, and percent change between 2006 and 2016 for both sexes combined for all GBD causes and levels 1 through 4 of the cause hierarchy	4	16	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	15.879557	1.7813718	53.831093	103.4877	-131.56413
223	223	Observed  (obs)  and expected  (exp)  numbers and standardised incidence ratios  (SIRs)  for all cancers in 42277 siblings of children with cancer, stratified by age at diagnosis	2	13	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	7.661453	2.682441	28.896902	55.287785	-101.001755
224	224	Female relative risk of death at ages 1574 years, by proxy-reported alcohol intake  (other drinkers vs reference drinkers, excluding never-drinkers)  and certified cause  (other causes vs control diseases)	4	20	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	22.208311	11.570216	13.105837	-65.53999	175.69519
225	225	Observed  (obs)  number of sibling pairs with cancer and standardised incidence ratios  (SIR)  in siblings of children with cancer, followed-up in adulthood, stratified by type of cancer of index patient	2	17	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	1.559126	19.377674	-31.126398	-68.45127	-64.938614
226	226	Incidence rates  (per 100 person-years)  and HRs for all incident cancers, lung cancers, and non-lung cancers	2	8	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	10.621858	2.5855525	27.185482	163.56226	-80.40139
227	227	Top ten causes of years lost due to disability  (YLDs)  in males, females, and both for ages 1014 years, 1519 years, and 2024 years, 1990, 2005, and 2013	4	11	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	18.731964	6.488653	-1.1696035	79.734146	-79.88231
228	228	Age-adjusted rates for all-cause, cardiovascular disease, and ischaemic heart disease mortality by sex-specific ascorbic acid quintile in men and women	4	14	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	10.640011	4.763605	-45.08871	110.13386	-48.00067
229	229	Death rates  (per 1000 person years) , number of deaths, and mortality ratios for various causes of death among men aged 4455 years, according to diabetic  (NIDDM)  and non-diabetic  (non-DM)  status in the Whitehall, Paris Prospective, and Helsinki Policemen studies	4	19	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	12.706615	0.47278157	-41.685833	136.41522	-130.1033
230	230	Decomposition analysis of the change of global years lived with disability  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific years lived with disability rates	4	24	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	14.114974	22.490364	130.87851	-14.00097	-6.583866
231	231	Age-standardised 5-year net survival  (%)  with 95% CI: adults  (1599 years)  diagnosed with one of seven common malignancies  (breast, cervix, ovary, prostate, brain, myeloid, and lymphoid)  and children  (014 years)  diagnosed with one of three common malignancies  (brain, acute lymphoblastic leukaemia, and lymphoma)  by continent, country, and calendar period of diagnosis	2	31	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-25.249706	14.301627	-27.363018	42.57546	16.171125
232	232	Decomposition analysis of the change of DALY numbers  (thousands)  by level 1 causes from 1990 to 2010 into total population growth, population ageing, and changes in age-specific, sex-specific, and cause-specific DALY rates for the Arab world	4	22	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	13.648271	22.869974	115.11261	7.444635	-13.079974
233	233	Unadjusted breast-cancer incidence and mortality from incident tumours, with unadjusted and adjusted relative risks of breast-cancer death	2	10	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	8.196581	4.8038826	-107.95519	65.72012	-108.79354
234	234	Relative risks  (95% CIs)  of death from all causes, cardiovascular disease  (CVD) , coronary heart disease  (CHD) , stroke, and external causes by typical dose per occasion in men who drink at least once a month	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-16.920696	-20.840971	138.25261	-54.303974	-0.23917231
235	235	Substance use disorders as predictors of all-cause mortality, suicide, and deaths from accidents in people with schizophrenia, bipolar disorder, or depression	4	13	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-1.9233515	3.666151	-9.244428	21.048058	-44.392773
236	236	Observed and expected deaths from breast cancer  (diagnosed in all years)  in the initial cohort within 16 years, andrate ratios  (intervention centres vs combined comparison centres)	2	14	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	9.133413	-18.826574	-85.77242	-144.90204	-17.676828
237	237	Age-standardised death rates, YLLs, and YLDs, and life expectancy at birth and HALE at birth for 1990 and 2010 for both sexes combined	4	11	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	14.373878	3.3741105	17.919128	114.50741	-106.565186
238	238	Deaths  (in thousands)  and age-standardised death rates per 100000 for 231 causes in 1990 and 2010 for all ages, both sexes combined, and percentage change from 1990 to 2010 in China	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	14.438255	2.127792	-10.627942	132.9414	-83.37417
239	239	Cardiovascular disease mortality according to overweight at age 8 years  (childhood)  or at age 20 years  (young adult age) , or both	4	10	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-3.8132904	1.0186247	50.458145	122.951004	-50.233112
240	240	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD related to absolute values of birthweight	4	9	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-13.93589	27.497377	-10.64794	16.6963	59.531387
241	241	Comparison of time trends in premature mortality before and during the 2008 economic crisis, by cause of death  (ICD-10)   *   and socioeconomic groups     and household car ownership, in the 2001 Spanish Census Cohort of people aged 1074 years	4	11	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-2.1659977	-9.680903	-49.11689	-31.626177	-75.154785
242	242	Relative risks  (95% Cis)  of death from all causes, cardiovascular diseases, and coronary heart disease, by frequency of drinking, stratified by typical dose per drinking occasion-drinkers only	4	16	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-16.916506	-20.836403	-162.97177	40.725426	-53.650578
243	243	Relative Rates  (95% CI)  of CVD Mortality, Incident CHD, and Total Mortality in Gender-Specific Quintiles of the Heart Rate-Adjusted QT	4	10	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	2.0424664	14.432204	-102.593155	-22.694387	-32.159603
244	244	Standardised incidence rates for endometrial and breast cancer per 1000 women over a 5-year period in current users and never users of HRT at recruitment	4	7	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	9.347082	1.2955735	-89.30298	86.58416	-147.51074
245	245	Exposure rates and odds ratios for wheeze and skin sensitivity to D pteronyssinus adjusted for age, sex, and urban or rural residence	0	5	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	9.746462	3.769874	-59.100178	105.3177	-86.09965
246	246	Global deaths, disability-adjusted life-years, and age-standardised rates attributable to ambient particulate matter pollution in 2015	4	10	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-3.5868773	-0.028597923	32.661762	96.495	-54.09764
247	247	Global deaths for 235 causes in 1990 and 2013 for all ages and both sexes combined and age-standardised death rates	4	9	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	14.502392	2.4983566	-171.19109	-48.493076	6.076759
248	248	Adjusted incidence rates, hazard ratios, and 95% CIs for cigarette smoking and lung cancer by sex	2	8	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	9.328718	3.4752243	-126.97146	-79.94318	-62.219364
249	249	Crude and adjusted hazard ratios  (95% CI)  for death from any cause, death due to IHD, and admission for or death from IHD in relation to combinations of adverse obstetric outcomes	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-13.934188	27.49894	48.821033	-15.099545	-196.14682
250	250	Diagnostic performance of Xpert MTB/RIF assay compared with smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-13.862246	-13.761244	45.73439	120.96316	78.32055
251	251	Subset Intravascular Ultrasound Analyses of Changes in the Cross-sectional Area of Lumen External Elastic Membrane and Plaque+Media  legend	3	14	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.51721144	-12.016857	-54.050613	-167.0372	6.2286663
252	252	Diagnostic accuracy of PECARN, CATCH, and CHALICE clinical decision rules when analysed using rule-specific inclusion criteria, exclusion criteria, predictor variables, and outcome measures	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-9.132906	-5.436092	36.324924	-176.91174	-1.1058482
253	253	Diagnostic performance of Xpert MTB/RIF assay compared with the combined reference standard  (smear microscopy, Lwenstein-Jensen medium, and Bactec MGIT960 system)	5	14	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.058632	-13.679115	30.579626	107.940735	88.23755
254	254	Per-protocol relative sensitivity and PPV of HPV versus Pap for a CIN2 or worse endpoint in different age groups with different cutoffs of HPV tests	0	7	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-7.9587145	18.863285	85.66268	-116.225716	112.47704
255	255	values on agreement of goitre diagnosis between examiners A, B, and C, between different classification systems in morning sessions, and between morning and afternoon sessions with the same classification system	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-6.245968	-10.556863	-64.69946	184.86888	-20.476664
256	256	Axial Distribution of the Changes in Lumen, External Elastic Membrane and Plaque Plus Media Cross-Sectional Areas  (according to individual slices)	3	16	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.5143363	-11.656633	-18.879072	81.4817	19.604511
257	257	Proportion of participants reporting at least one severe rotavirus gastroenteritis  (RVGE)  episodes  (per protocol clinical definition)  and vaccine efficacy against severe RVGE during three efficacy periods  (according-to-protocol cohorts for the 2-years' efficacy subset)	4	22	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	8.666982	11.424666	-57.945255	88.67971	44.3536
258	258	Performance of smear microscopy, clinic-based nurse-administered Xpert MTB/RIF, and laboratory-based technician-administered Xpert MTB/RIF, per treatment site and overall	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.083752	-15.0151415	9.265564	135.9316	91.24348
259	259	Inclusion and exclusion criteria, predictor variables, and outcome measures of PECARN, CATCH, and CHALICE clinical decision rules  8,9,12	7	8	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-9.034985	-5.4580417	-59.912758	67.57548	-111.52299
260	260	Efficacy of RIX4414 against severe rotavirus gastroenteritis and severe gastroenteritis during the 2-years' efficacy period  (ATP cohort for the 2-years' efficacy subset)	4	13	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	9.495199	10.800019	65.66168	-9.26409	-15.713384
261	261	Epinephrine-Induced Changes in the max QTc-e, the min QTc-e, the QTc-eD, the max QTc-p, the min QTc-p, and the QTc-pD, Which Are Obtained From all 87-Leads, in the LQT1, LQT2, and Control Patients legend	5	7	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-3.2911425	-25.229229	-70.51127	77.78688	101.155556
262	262	Effect of Using Different Cutoff Values for BNP on Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, and Accuracy in Predicting Death  (All-Cause Including the Cardiac Death)  in Referred and Not-Referred Groups	0	21	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.66979	-10.134121	-44.45315	149.12756	5.7640486
263	263	Findings for all 441 women who were negative on initial colposcopy and were called back for a second colposcopy, including four-quadrant cervical biopsies and endocervical curettage, because of unsatisfactory or ASC-H+ cytology, positive careHPV  (RLU/cut-off ratio cut-point of 05) , or positive HC2 findings	2	12	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-9.5252905	-7.906121	-9.256332	120.14446	-6.666094
264	264	Determining Central SBP Cutoff Values Based on the Sensitivity and Specificity Associated With Cuff SBP Cutoff Values for Predicting Cardiovascular Mortality	0	12	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-12.389719	-7.366976	-87.86601	121.58021	12.80454
265	265	Vaccine efficacy against any and severe rotavirus gastroenteritis according to detected rotavirus G types  (according-to-protocol cohort)	4	12	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	7.85561	9.034916	31.350758	28.761929	39.684284
266	266	False-positive recall proportion shown according to double-reading protocols, and comparison of false-positive recall for screening integrating 3D mammography vs standard 2D mammography alone	0	14	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-8.478536	-12.083496	-16.639738	179.07759	60.01612
267	267	Comparisons of Area Under the ROC Curve Along With LR+ and LR for BNP or NT-proBNP Assays to Diagnose or Exclude Acute HF in Various Large Trials of Acute Dyspnea	7	5	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-22.552927	0.6079661	64.81946	-111.01152	46.909134
268	268	Sensitivity, Specificity, Positive Prognostic Value and Negative Prognostic Value of the Ability to Exercise to Bruce Stage 3 and a Duke Score 6	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-13.089962	-9.383361	-48.02823	134.97961	54.96576
269	269	Vaccine efficacy against any and severe rotavirus gastroenteritis, admission, and medical attention  (according-to-protocol cohort)	4	11	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	8.232572	9.01209	160.94492	-82.07003	14.95771
270	270	The Number of Patients With True-Positive, False-Negative, True-Negative, and False-Positive Test Results	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-9.375094	-11.208464	-6.781879	165.28038	30.305935
271	271	Vaccine efficacy against cervical intraepithelial neoplasia grade 2 or more  (CIN2+) , or grade 3 or more  (CIN3+) , colposcopy referrals, and cervical excision procedures associated with human papillomavirus  (HPV) -16/18, five non-vaccine oncogenic types, and irrespective of HPV DNA in lesion	6	12	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	11.043375	8.57668	25.807798	-4.156691	20.97587
272	272	Relative sensitivity and specificity for CIN2+ and sensitivity for CIN3+ under different screening policies based on 220 CIN2 and 233 CIN3+ histologies detected in 18386 women in the revealed group in round 1	0	9	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	12.963673	6.8516273	128.06451	68.335075	-82.19819
273	273	Individual Components of Secondary Efficacy Endpoint of Persistent WRF	4	4	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	-4.284189	2.7034264	-3.8607337	33.83599	-142.06871
274	274	Sensitivities, specificities, positive and negative predictive values, and probabilities for comparison of differences in sensitivities	0	10	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-8.738688	-8.825275	5.3000526	1.8668542	181.5459
275	275	One-Year Outcomes for the Lean, Overweight, and Obese Categories Stratified by Median BNP  (452 pg/ml)	2	2	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	0.75308573	1.6364676	-51.84204	86.35091	-2.6969507
276	276	Sensitivity, specificity, positive predictive values, and negative predictive values, by CSF -synuclein cutoff value	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.602945	-8.49243	-67.568016	126.57256	-6.4018517
277	277	Comparison of acid-fast-bacilli smear-positive, smear-negative, and smear-indeterminate patients	5	7	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-10.694953	-12.312154	18.305342	139.04677	37.368378
278	278	Diagnostic sensitivities  (SE) , specificities  (SP) , false-negative  (FN)  and false-positive  (FP)  cases in each conventional BIT subtest and in combinations of two and three subtests  (n=52)	0	12	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-8.030501	-9.354555	31.169313	148.72667	-4.2591915
279	279	Proportion of participants reporting severe rotavirus gastroenteritis  (RVGE)  episodes with a score of 11, 19 and 20 on the Vesikari scale and efficacy of vaccine during the 2-years' efficacy period  (according-to-protocol cohort for efficacy)	4	19	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	9.375142	11.723353	75.92783	8.609986	-35.153973
280	280	Pooled estimates of associations of TP53 codon 72 genotype and cervical histology of 33 studies; and invasive cervical cancer cases of 25 studies in subgroups of HPV status, ethnic group, and different quality criteria	3	9	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-2.6442807	18.37514	-132.72241	-128.61987	-10.632232
281	281	Interim Operative Procedures Performed in 38 Stage I Operative Survivors Before Stage II Operation	7	7	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-8.113149	-1.6417605	159.13591	-37.536964	-41.787823
282	282	Subgroup Analyses for Death, Major Amputation, Likelihood of Any Revascularization, and Likelihood of Endovascular Revascularization in the Study Cohort on the Basis of A PrioriDefined Subgroups	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-13.94087	7.826564	-102.38361	-161.96239	24.224987
283	283	Summary of Studies That Used Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Analyzed Separately	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-23.223724	-16.576994	152.11017	91.24011	82.1894
284	284	Ratio of Actual THV Stent Area Measured With CT to Nominal THV Area According to THV Size and Degree of Underfilling	1	6	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-21.95388	-4.194685	-122.08099	91.89954	119.64668
285	285	Patients with a positive smear microscopy, Xpert MTB/RIF, or culture result, and days to result, per allocation group	5	8	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-12.473824	-13.762528	35.801704	147.86798	67.977936
286	286	Hazard Ratios for Different Endpoints per 1 SD Increase of ST2 Level or NT-proBNP Level  (on the Log2 Scale)  at Any Point in Time Using Repeated ST2 and Repeated NT-proBNP Measurements in a Joint Model	0	8	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-19.151447	11.3435955	-165.9688	-18.6057	88.32402
287	287	Stent thromboses according to ARC criteria for definite stent thrombosis and according to per-protocol definitions used in individual trials	7	6	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	9.448365	-4.7279906	54.125942	13.276346	58.379368
288	288	Sensitivity, specificity, and positive and negative predictive value for retinopathy at different fasting plasma glucose cutoffs	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-10.731329	-8.785378	77.08723	-147.56581	14.456687
289	289	Lumen Area, Vessel Area and Plaque Area of Cross Sections Arranged in the Six Sections  legend	3	9	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.79480994	-13.112313	-51.26342	115.54079	110.05138
290	290	Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Various Cut-Off Values for the Indicated Parameters	0	11	model(35),regress(33),multivari(24),hazard(24),heart(23),analysi(23),ventricular(23),proport(21),valu(21),differ(20)	-11.541241	-8.904532	-75.401024	-120.39818	75.81928
291	291	Effect of the 9vHPV vaccine on the incidence of persistent infection, cervical disease, cervical cytological abnormalities, and cervical definitive therapy related to each HPV type in the per-protocol efficacy population	4	9	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	6.378232	15.235002	-35.30187	-26.512625	187.61713
292	292	APOE genotypes of AD patients and aged non-AD patients positive or negative for HSV1 in brain  (frontal lobe and temporal lobe)	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-6.0380635	-8.261953	45.343838	181.82637	-37.475822
293	293	Efficacy against CIN2+ and CIN1+ associated with HPV16 or HPV18 in the total vaccinated cohort for efficacy	4	5	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	10.021733	8.627487	28.113031	5.0346074	-5.5362477
294	294	Vaccine efficacy against all-cause severe gastroenteritis and admission  (according-to-protocol cohort for efficacy)	4	10	death(39),year(37),caus(31),rat(24),mortal(17),efficaci(17),specif(15),adjust(14),age(13),drinker(13)	8.780006	9.220578	90.98031	-18.417198	-158.51595
295	295	Key Eligibility Criteria and Key Exclusion Criteria	7	4	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-5.2410474	-0.12641461	427.83115	-37.341946	-170.32047
296	296	Value of the Aortic Effective Regurgitant Orifice Area Calculated With the Proximal Isovelocity Surface Area Method and Quantitative Doppler and Two-Dimensional Echocardiographic Methods in the Overall Study Group and in Subgroups of Patients	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-0.9362559	-13.587127	-79.73016	129.20174	94.99127
297	297	Percentage of Total Cross Section Represented by Plaque Area  (Difference Between Lumen Area and Area Delimited by Internal Elastic Lamina)  at Either 7 or 21 Days After Treatment with rhVEGF  (2 g/kg by a Single Intramuscular Injection)  or Albumin legend	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	1.6478765	-13.720985	-33.173103	98.50506	126.3105
298	298	Summary of Studies That Use Measured EOAi to Assess VP-PM: Data of Moderate and Severe VP-PM Are Combined	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-23.228262	-16.57495	-167.86801	-91.39182	-28.07282
299	299	Comparison of ARIC JUPITER-Eligible Group, JUPITER Placebo Arm, and JUPITER Treated Arm: Event Rates	7	10	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-0.082003824	-8.84188	158.67738	34.633255	-112.70647
300	300	Per Vessel Territory Diagnostic Accuracy of Coronary Computed Tomography Angiography, Transluminal Attenuation Gradient, Contrast Opacification Difference  (Maximum, Mean, and Minimum) , and Quantitative Coronary Angiography Compared With Fractional Flow Reserve  (N = 78)	5	22	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-18.637222	1.6550251	21.397076	-125.80777	-141.91675
301	301	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	6	19	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	2.0254934	-22.08405	33.52234	-115.100746	128.77026
302	302	Basal and  () Isoprenaline-Stimulated cAMP-levels of CHW-beta1 Cells in the Presence of Rabbit  (70 nmol/liter) , Mouse  (7 nmol/liter) , or Human Anti-beta1-ECII  (2 mol/liter)	6	18	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	2.0254934	-22.08405	33.52234	-115.100746	128.77026
303	303	Comparison of MR, Doppler Echocardiography and Catheterization-Derived Peak Pulmonary Vein Blood Flow Gradients  (mm Hg)  in Patients With Pulmonary Venous Pathway Obstruction	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	0.15605253	10.20326	72.55524	-20.981077	-77.739
304	304	Individual Peak Myocardial Videointensity Data  (in gray scale units)  in Middle and Lateral Segments of Original Stenosis Zone and Adjacent Perfusion Bed in the Presence of One- and Two-Vessel Stenosis During Both Rest and Dobutamine Stress Echocardiography	5	21	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-4.271465	-9.410823	8.022312	-8.578871	-113.94657
305	305	Peak Tissue Doppler Velocity at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-24.072115	6.411316	-40.57965	-85.93712	160.23839
306	306	Comparison of Magnetic Resonance Imaging Findings Based on Dobutamine-Induced Systolic Wall Thickening and End-Diastolic Wall Thickness With Postrevascularization Recovery of Systolic Wall Thickening	5	18	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-11.658098	-2.296315	-86.72272	-118.44342	-57.13625
307	307	Coronary Flow Velocity Change in Coronary Aneurysms at Rest and Coronary Flow Reserve in 25 Patients With Kawasaki Disease and Aneurysmal Lesions in 29 Coronary Vessels  (group 2)	5	18	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-18.80224	-2.6877208	105.03105	-96.88945	-103.71131
308	308	Peak Systolic SR Data at Rest and During Dobutamine Stimulation Related to Results of 18F-Fluorodeoxyglucose Positron Emission Tomography for 192 Dyssynergic Segments at Rest	5	14	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-24.0816	6.3572483	-28.627165	-101.46096	-152.9617
309	309	Forearm Blood Flow During Brachial Artery Infusion of Saline, l-Arginine Alone, Nitroprusside, Acetylcholine and Acetylcholine Plus l-Arginine in Control Subjects and Hypertriglyceridemic Patients	5	16	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-2.7858493	-5.920503	83.12703	-61.43283	-126.99006
310	310	Coronary Flow Velocity Dynamics in Eight Patients With Kawasaki Disease and Ischemic Findings on Exercise Stress Testing and Normal Coronary Arteries on Angiography  (group 4)	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-18.426895	-2.1745145	-59.693676	15.329394	161.14484
311	311	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	7	17	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-4.922045	-25.250433	119.97055	118.7562	-36.980217
312	312	Variable Inter-Compression Analysis Between the Repeated Measurements  (t1)  of 48 Coronary Obstructions in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Measurements  (t0)  in the Original Image Series legend	7	17	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-4.922076	-25.25025	-42.503956	53.850357	101.94603
313	313	Peak Pulmonary Vein Blood Flow Velocity  (cm/s)  of Patients With Pulmonary Venous Pathway Obstruction from MR Velocity Mapping and Doppler Echocardiography legend legend	5	16	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-8.200173	0.755677	68.83848	-42.53442	-84.16249
314	314	Sensitivity of Dipyridamole, Dobutamine Stress Echo and Myocardial Perfusion Scintigraphy for the Detection of Isolated Left Anterior Descending Coronary Artery Disease With and Without Multivessel Disease legend	5	17	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-12.794787	0.5464392	-7.017238	-159.9326	-96.51827
315	315	Per-Vessel Territory Diagnostic Accuracy of QCA, Coronary CTA, Combined CTA+ CTP, Combined CTA+ TAG320, and MDCT-IP Assessments, Compared With FFR	5	10	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	10.794287	-2.0473628	-51.31211	-127.037735	-117.80408
316	316	Value of Response to Dobutamine at the First Week  (Wall Thickening With Dobutamine >2 mm)  for Predicting Normal Segmental Wall Motion at the Sixth Month  (Wall Thickening >2 mm)  Depending on the Transmural Extent of Necrosis	5	13	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-3.2832558	-19.537817	-99.7436	-124.59775	-89.40257
317	317	Diagnostic Performance of Multislice Spiral Computed Tomography Coronary Angiography for the Detection of Significant Obstructive Lesions	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-16.390913	3.700398	159.51572	-24.307383	72.418236
318	318	Contractile Responses to Potassium  (K+125 mmol/liter)  Phenylephrine  (PE, 1 mol/liter)  and Angiotensin II  (1 and 100 nmol/liter) , and Dilator Responses to Acetylcholine  (10 mol/liter)  in Human Internal Mammary Artery Segments From Patients With the DD or the II/ID Genotype legend	6	16	event(76),advers(70),treatment(70),patient(31),grade(30),group(30),popul(28),emerg(22),safeti(22),studi(16)	2.7332747	-21.176851	23.458208	-90.23945	110.80061
319	319	Comparison of Thallium-201 and Technetium-99m Tetrofosmin Single-Photon Emission Computed Tomographic Dipyridamole Imaging Data in 364 Scan Segments	5	14	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.269017	-2.5124528	38.351856	-36.098198	-114.38451
320	320	Diagnostic Accuracy of Two-Dimensional Dobutamine Stress Echocardiography, TDI and SRI for Detection of Viability Determined by 18F-Flurodeoxyglucose Positron Emission Tomography	5	11	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-20.005665	3.6962397	-85.35235	-89.24653	-139.13477
321	321	Variable Inter-Compression Analysis Between the Repeated Calibrations  (t1)  of 48 Catheters in the Original and the Compressed/Decompressed  (CR 6, 10 and 16)  Image Series and the First Calibrations  (t0)  in the Original Image Series legend	7	16	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-4.66404	-24.780254	-57.254242	53.6071	79.57337
322	322	Pulse, Systolic Blood Pressure, End-Tidal Carbon Dioxide Concentration and Arterial Oxygen Saturation at Rest, at 3 Minutes of Exercise, at 6 Minutes of Exercise and at Peak Exercise With Placebo and Dihydrocodeine	5	20	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-24.454159	4.469927	-54.907055	-26.036215	-109.50912
323	323	Diagnostic Accuracy of Whole-Heart Coronary Magnetic Resonance Angiography to Detect Stenoses of 50% in 113 Patients Who Completed Acquisition of Coronary Magnetic Resonance Data	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.65694	3.7912505	16.051178	-181.5494	-55.128754
324	324	Analysis of Significance and Prognostic Value of Systolic Blood Pressure, Diastolic Blood Pressure and Mean Arterial Blood Pressure Obtained During Dobutamine Infusion  a	5	14	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-10.845483	2.9243245	-22.576427	-55.41751	-159.15395
325	325	Analysis of the Influence of Coronary Diameter, Image Quality, and Coronary Calcium of the Diagnostic Performance of 64-Slice CTCA for the Detection of 50% Stenosis on QCA in the Per-Segment Analysis  (95% CI)	5	14	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-16.02795	6.507658	-36.492363	-137.76309	-33.90304
326	326	Cutpoints for Electron Beam Computed Tomographic Coronary Calcium Scores for Sensitivity of 90% and Associated Specificity and for Electron Beam Computed Tomographic Quantified Coronary Calcium Scores for Specificity of 90% and Associated Sensitivity as a Function of Decade of Associated Maximal Angiographic Lumen Stenoses	5	22	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-18.455814	5.107989	-16.316467	-108.28331	-94.40565
327	327	Relative Coronary Flow Reserves for Adenosine and Papaverine and Volumetric Coronary Flow Reserve for Acetylcholine in Five Patients with the Adenosine Defect and Twenty-Four Control Subjects	5	16	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-3.6605644	-11.808574	92.22376	-99.09714	-140.63701
328	328	PET Flow and Glucose Uptake, Percent MIBI Uptake, Ventricular Function and Percent Fibrosis in Anterior Wall Biopsy Specimen	5	9	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-6.5810165	-2.635342	96.9222	33.857452	-142.15317
329	329	Relationship Between Coronary Artery Lesions and Perfusion Defects on Thallium-201 Single Photon Emission Computed Tomography	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.80535	-2.4029355	40.06236	-17.782475	-132.65227
330	330	Intensity of Single-Photon Emission Computed Tomographic Perfusion Defects, Wall Motion Abnormalities and Contrast Effects on Patients in Each Randomized Dosage Group legend	5	17	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-15.544879	-2.8467524	48.499302	-35.086796	-152.78307
331	331	Comparison Between Intravenous Electron-Beam Coronary Angiography and Selective Coronary Angiography in 221 Segments Comprising the Proximal and Mid Major Coronary Arteries  (eight-segment model)  in 28 Patients  legend	5	15	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-18.808666	-0.81610596	41.666367	-78.8512	-89.43031
332	332	Diagnostic Performance of SPECT, CMR, and PET Perfusion Imaging on Patient and Coronary Artery Territory Basis	5	9	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-13.883417	-0.23131797	54.933807	-105.716286	-112.13645
333	333	Results: Detection of Significant  (50%)  Stenoses With 16-Row Multislice Spiral Computed Tomography Coronary Angiography	5	10	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-16.325794	2.8798232	-62.962643	-49.358322	-143.21754
334	334	Quantitative Measurements of Wall Thickness, Simulated Wall Motion and Simulated Wall Thickening Using the Variable Thickness Heart Phantom	5	11	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-11.246205	-2.0621207	-77.20299	-104.1071	-77.88282
335	335	Detection of Significant Coronary Stenoses by Electron Beam Computed Tomography Versus Coronary Angiography for 267 Analyzed Segments	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-17.161034	2.993145	8.735819	-90.50003	-115.8521
336	336	Results of Quantitative Computerized Digital Analysis of Micro-CT Images by Normal and the Balloon-injured Coronary Arteries	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-10.337966	1.0758508	-50.809937	-2.873274	72.235794
337	337	Correlation of Single-Photon Emission Computed Tomography  (SPECT)  With Harmonic Myocardial Contrast Echocardiography in the Triggered Mode, According to the Correlation of SPECT with Wall Motion Analysis  (After Exclusion of Nondiagnostic Studies)  legend	5	20	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-19.13897	-14.036281	-54.93884	-182.99966	-47.07455
338	338	Performance Indexes of CTCA and SPECT/CTCA for Detection of Hemodynamically Significant Coronary Lesions in 170 Segments in 44 Patients	5	10	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-15.854189	0.31886196	4.914414	-65.986275	-85.058334
339	339	Results of Magnetic Resonance Imaging Parameters and uptake by Positron Emission Tomography, According to Wall Motion	5	12	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-10.272665	-1.3726854	-30.192625	12.421307	96.6587
340	340	Mitral Inflow, Pulmonary Venous Flow and Mitral Annulus Velocity in 59 Normal Volunteers	5	6	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-6.150498	-1.144288	53.245693	17.246473	-71.40358
341	341	Diagnostic Performance of RT-MCE and SPECT to Detect Significant Coronary Artery Disease in Individual Vascular Territories	5	10	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-14.160151	0.72231174	4.497459	53.289845	50.32631
342	342	Diagnostic Accuracy of Coronary CTA for the Detection of Acute Coronary Syndrome and Myocardial Infarction During Index Hospitalization Among Patients With Acute Chest Pain Based on the Presence of Any Coronary Plaque or the Presence of Coronary Artery Stenosis  (>50% Luminal Narrowing)	5	13	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-16.808348	6.780988	-10.010085	-143.81018	-46.76881
343	343	Results of Coronary Artery Segment Classification and Stenosis Assessment by Contrast-enhanced Magnetic Resonance Coronary Angiography Compared With Conventional Invasive Angiography  (n = 350)  legend	5	17	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-17.304924	1.4862177	22.049562	-128.09569	-104.10025
344	344	Diagnostic Performance of Multi-Slice Computed Tomography Coronary Angiography to Detect 50% Stenoses	5	10	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-15.487704	2.6656208	-54.02172	-22.845486	-145.27165
345	345	Comparison of MCE, SPECT, Wall Motion and the Combination of MCE and Wall Motion With Results of Coronary Angiography: Analysis by Patients  (n = 44)  legend	5	13	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-10.781417	-0.099522255	-64.816864	-156.32802	-68.38324
346	346	Per-Vessel Diagnostic Accuracy of CTA+ TAG320, CTA+ CTP, and MDCT-IP Methods in 97 Vessels	5	5	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	10.7044115	-2.018643	-17.289034	-36.20254	-26.134748
347	347	Mean Myocardial Perfusion Measures Across Number of Coronary Arteries Containing Calcium  (Coronary Artery Calcium Score >0 in the Respective Artery)  in Subjects With No Clinical Coronary Heart Disease From The Multi-Ethnic Study of Atherosclerosis	5	17	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-13.708766	1.941788	61.259	-162.6667	-42.469646
348	348	Comparison of Superior Vena Cava Peak Forward and Reverse Flow Velocity in Chronic Obstructive Pulmonary Disease and Constrictive Pericarditis  legend	5	11	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-7.1159196	-0.70151263	33.034878	-7.264445	-80.027145
349	349	Accuracy of Multislice Computed Tomography for the Detection of Significant Coronary Plaque    : Comparison With IVUS for the Entire Region of Interest and for its 5-mm Subsegments	5	13	coronari(44),patient(19),arteri(16),wall(15),legend(15),diagnost(13),angiographi(13),detect(12),flow(12),tomographi(12)	-17.22225	5.0691824	-29.69942	-120.31887	-69.2276
350	350	Overview of Used Risk Scores: Risk Factors Used in CHA2DS2-VASc Risk Score and CHADS2 Risk Score	3	11	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	2.7634988	10.715983	-57.581894	-85.26089	105.09386
351	351	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	3	13	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-15.159849	16.641117	58.23424	46.44166	189.34969
352	352	Comparison of CHA2DS2-VASc and CHA2DS2-VASc-R Scores in Predicting Stroke: Relative Hazard Associated With 1-Point Increase in Stroke Risk Score, and C-Statistic	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-15.159798	16.641388	-42.845036	-75.95013	-109.67776
353	353	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-17.494467	19.135908	-88.08287	-44.96466	155.09949
354	354	Hazard of Stroke by Race/Ethnicity, Relative to White Patients, After Controlling for CHA2DS2-VASc Score  (Model 1)  and CHA2DS2-VASc Score Plus Anticoagulant Use  (Model 2)	3	13	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-17.494467	19.135908	-88.08287	-44.96466	155.09949
355	355	ORunadjusted and ORadj-2 of morbidity at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	3	18	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-5.1249804	28.01062	24.01347	-91.4649	47.0871
356	356	7-day risk of stroke stratified according to ABCD score at first assessment in all referrals with suspected TIA to OXVASC and risk of stroke before scheduled clinic appointment in all referrals with suspected TIA to the non-OXVASC hospital-referred weekly TIA clinic	7	14	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	-11.981431	14.249731	-2.5741107	-94.146484	80.2311
357	357	ORunadjusted and ORadj-2 of mortality at 30 days for patients with anaemia or risk factors and anaemia and risk factors, compared with reference populations of patients with neither anaemia nor risk factors	3	16	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-5.1246943	28.011028	35.446533	-78.82731	61.304783
358	358	Association of Age, Sex, and Race/Ethnicity With ABI Category, and Age-, Sex-, and Race/Ethnicity-Adjusted Distributions of Risk Factors by ABI Category	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-0.027722614	-16.77726	-37.19719	91.25503	-165.53462
359	359	Association of TG or TG Genetic Risk Score With CAC 75th Percentile in the FHS	3	5	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-9.689008	10.635304	-98.713554	-38.023846	68.588234
360	360	Relative Risk of Incident CAC and Mean Change in CAC Score With Varying FRS and RRS Groups According to Low- and High-Risk Groups Classified by FRS and RRS, Respectively	3	12	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	5.624909	6.2695646	11.655427	61.74322	-28.079924
361	361	Pooled analysis of the early risk of recurrent vascular events, given per time period after randomisation, in trials of aspirin versus control in secondary prevention after transient ischaemic attack and ischaemic stroke	3	17	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	2.4210386	5.005601	-34.055103	-78.168274	-7.5978866
362	362	Risk of Ischemic Stroke in Patients with an ATRIA Score of 0 to 5, Stratified on the Basis of Their CHA2DS2-VASc Scores	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-12.550049	12.343711	141.15439	18.779644	106.100945
363	363	Western Aphasia Battery  (WAB)  subtest scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	3	14	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	11.403353	16.796328	-128.52495	-15.167682	-74.76108
364	364	Risk of Ischemic Stroke in AF Female Patients  (CHA2DS2-VASc Score of 2: Female Plus 1 Additional Stroke Risk Factor)	3	13	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-13.08405	12.828652	-24.54502	-116.241325	116.49794
365	365	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients with dominant hemispheric tumour who were dysphasic  (aphasia quotient <937)  before resection	3	14	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	11.46684	16.791328	151.09605	82.16342	-33.600555
366	366	Severity and duration of upper-respiratory-tract  (URT)  and lower-respiratory-tract  (LRT)  symptoms associated with rhinovirus infection	1	9	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-4.9362597	-6.6349998	91.85856	158.02303	-38.479965
367	367	Statistical associations  (p<10107)  between Illumina SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of three UK study populations consisting of up to 4337 participants	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	5.4496684	20.900803	-65.66847	-40.356464	112.694435
368	368	c statistics  (with 95% CI)  for early stroke discrimination with ABCD2, ABCD2-I, and ABCD3-I scores at each timepoint after transient ischaemic attack	3	12	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.29200697	6.286766	122.17131	88.816895	6.6755457
369	369	Association of Lipid Measures or Genetic Risk Scores With CAC 75th Percentile in the Pooled FHS Offspring and Third-Generation Cohorts  (n = 3,110)	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-9.715823	10.703679	-6.295229	-22.464262	53.51604
370	370	Ischemic Stroke Event Rates Stratified by the Sum of Points for ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores	3	11	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-12.192878	11.218127	-102.13377	-32.44683	-105.460754
371	371	Randomised controlled trials included in the systematic review and network meta-analysis	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-4.8613505	-1.2716	35.425232	36.786106	-45.26119
372	372	Statistical associations  (p<10107)  between Affymetrix SNPs and circulating concentrations of LDL cholesterol in a genome-wide meta-analysis of five study populations consisting of up to 11685 participants	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	5.4985204	20.888607	78.45024	-116.89534	-36.144676
373	373	Pooled analysis of the effect of any aspirin versus control in secondary prevention after TIA and ischaemic stroke on the early risk of any recurrent ischaemic stroke and on disabling or fatal ischaemic stroke stratified by the nature of the presenting event  (TIA and minor stroke vs major stroke)  and by time from presenting event to randomisation  (14 days vs >14 days)	3	33	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	5.1400657	-12.05671	-45.454697	-95.35319	-27.208612
374	374	Prevalence of Solo and Combination Antiplatelet Prescription in AF Patients at Intermediate to High Risk of Stroke, Stratified by Prescription of Aspirin Versus OAC in the Overall CHADS2 Score2 and CHA2DS2-VASc Score2 Cohorts and Subcohorts of Patients With and Without Any Coronary Heart Disease Risk Equivalent	3	22	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-14.744895	13.757165	-7.9928513	-114.091576	-8.219652
375	375	Adjuvant radiotherapy received  (within 3 months after surgery) , nodes removed, nodal status, and external-beam radiotherapy  (EBRT)  received in node-positive patients by risk group defined according to ASTEC radiotherapy eligibility	7	18	patient(49),hospit(22),acut(21),outcom(19),clinic(19),myocardi(18),infarct(17),legend(16),therapi(14),complic(10)	1.9668934	-5.4927673	118.18976	-7.466812	73.704956
376	376	Distribution of WHODAS disability scores by dementia status and site, and the effects of dementia  (main effect of 10/66 dementia, modified by DSM-IV dementia)  on WHODAS score	3	15	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-11.781779	-4.6665983	-148.88121	-31.188894	-120.17975
377	377	Drug Prescription Distribution Among Responders by Haplotype Arg389Arg-Ser49Ser  (n = 85)  and Arg389Gly-Ser49Ser  (n = 97)	1	4	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-5.5240946	0.89138514	-13.8253975	113.03671	38.242912
378	378	Vascular risk factors and retinal vascular signs in patients with lacunar and other ischaemic stroke	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	1.229738	3.7028644	-29.492899	138.9624	138.61934
379	379	Availability of data from randomised trials that began before 1990 of adjuvant tamoxifen versus no adjuvant tamoxifen	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-10.967811	17.04788	-60.810246	-168.28795	54.869995
380	380	Western Aphasia Battery  (WAB)  summary scores before and after resection for patients whose language was classified as normal  (aphasia quotient 938)  before resection	3	13	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	12.220596	16.745691	170.5859	64.55091	-44.543804
381	381	Imputed SNPs showing genome-wide statistical association  (p<10107)  with circulating concentrations of LDL cholesterol; meta-analysis of four study populations consisting of up to 9988 participants	3	16	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	6.0935445	20.796183	77.63193	-101.53654	-59.077805
382	382	Risk of transient ischaemic attack according to use of HRT and identified risk factors in women aged 4564 years	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	2.34937	7.241635	-23.183521	-99.34725	27.28023
383	383	Prevalence Rates of Major Cardiovascular Risk Factors in Patients With Familial P-CAD and Their Respective Age- and Gender-Matched Control Subjects, According to Parental History of CAD in Patients with Familial P-CAD *	3	14	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	3.3229592	2.9742503	35.202614	-140.63884	71.46916
384	384	Independent contributions to the risk of a second ischaemic stroke for prothrombotic risk factors, antithrombotic treatment, and stroke subtypes	3	12	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.07057967	4.953775	-10.230252	-66.09061	56.447628
385	385	Design of randomised trials of unfractionated heparin compared with placebo or untreated control in acute coronary syndrome without ST elevation	3	9	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-2.9479718	2.543297	42.01747	-122.317986	26.170633
386	386	Discrimination between benign and malignant thyroid lesions by CD44v6 and galectin-3 immunodetection on fresh cytological material from preoperative fine-needle aspiration	2	14	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	-14.15031	-4.6473975	-97.06342	151.0532	-44.37813
387	387	Risk of ischaemic stroke subtypes  *   associated with risk factors	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	0.4781001	4.995612	-81.764465	9.294239	-20.790346
388	388	Germline BRCA mutation status according to tumour BRCA mutation status	3	9	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-6.7329664	1.7322221	128.30045	132.46532	18.852707
389	389	Multivariable Logistic Regression Predicting the Likelihood of CAD According to Quartiles of LBP Levels, Markers of Systemic Inflammation, and Established Cardiovascular Risk Factors	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	1.3121337	8.39189	-46.783546	-128.91026	23.666674
390	390	Evaluating the Predictive Ability of the HAS-BLED Score Versus CHADS2 or CHA2DS2-VASc Score for the Detection of MajorBleeding Using C-Statistics, Relative NRI, and IDI Indexes	3	10	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-12.4842005	9.914321	-119.888054	-114.637596	99.790535
391	391	Description of haemostatic gene polymorphisms in this review and their associated intermediate phenotypes	1	7	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-4.227361	-1.2149621	-101.58869	41.14836	-4.6642447
392	392	Risk of intracerebral haemorrhage according to use of HRT and identified risk factors in women aged 4564 years	2	6	cancer(27),year(25),health(16),incid(15),surviv(13),ratio(12),standardis(12),child(11),diagnos(10),type(10)	2.3455863	7.3654003	45.012505	41.71218	-170.54318
393	393	Prevalence of different risk factors in cryptogenic versus other transient ischaemic attack and ischaemic stroke subtypes	3	11	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	1.3195457	4.8967724	-26.469904	-64.763626	16.880318
394	394	Women with hormone-receptor-positive tumours and who did not report either symptom at trial entry with vasomotor symptoms or joint symptoms at the 3-month follow-up visit according to treatment group	1	12	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	7.8508177	-3.0808246	64.699615	168.38493	88.898964
395	395	Overview of Used Risk Scores: Risk Factors Used in ATRIA Risk Score	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	2.7150016	10.59974	-36.26103	-80.340096	97.05723
396	396	Respiratory-chain enzyme activity in circulating lymphocytes of patients 1 and 3 and of 163 controls	1	5	intervent(18),method(14),modern(13),estim(12),incom(11),countri(11),level(10),women(10),effect(8),physic(8)	-3.8769763	-6.3807607	-378.51962	-448.34064	-735.09845
397	397	SLC6A3 mutations identified in patients with dopamine transporter deficiency syndrome	3	7	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	-2.4894235	-0.23708719	-114.99548	13.517767	-18.78127
398	398	Relative Risk of Incident CAC Associated With Increasing Risk Categories According to FRS and RRS Classification	3	8	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	4.492751	5.904714	-46.584805	-188.3074	-98.0307
399	399	Mean Change in CAC Score  (Agatston Units)  Associated With Increasing Risk Categories According to FRS and RRS Classification	3	9	risk(52),score(37),stroke(27),patient(23),factor(19),associ(18),vasc(14),accord(13),ischaem(13),area(13)	4.571764	5.796776	4.72085	35.56269	-9.357705
